Compare ARK Genomic Revolution ETF (ARKG) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Otis Worldwide Corp — how do they compare? ARK Genomic Revolution ETF trades at $40.6, while Otis Worldwide Corp trades at $73.65 (market cap $28.05B). The key difference: Otis Worldwide Corp pays a 2.33% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Otis Worldwide Corp nearer its low. Which is the better fit depends on your goals.
| ARKG | OTIS | |
|---|---|---|
Sector | Sector/Thematic | Industrials |
52-Week High | $43.57 | $101.07 |
52-Week Low | $23.09 | $69.34 |
Market Cap | — | $28.05B |
Enterprise Value | — | $35.43B |
Dividend Yield | — | 2.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Otis Worldwide trades at $73.09, up 1.51% today, amid a bearish technical signal despite neutral oscillators. The company reported mixed quarterly earnings, with Q1 2026 missing estimates, but maintains steady revenue growth and a 10.11% net income margin. Recent news highlights strategic modernization projects and a 5% dividend increase, while analyst consensus remains cautiously optimistic with a $94 price target.
The stock presents a value opportunity with a P/E of 19.44 below historical averages, but faces headwinds from China exposure and margin pressure. Upside potential exists if earnings rebound, though high debt and competitive risks warrant caution for investors seeking stable industrial exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
